Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review
about
Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical SensingIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesCost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration.Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression.Intravitreal crystalline drug delivery for intraocular proliferation diseases.Gene transfer using micellar nanovectors inhibits choroidal neovascularization in vivoInterventions for Age-Related Macular Degeneration: Are Practice Guidelines Based on Systematic Reviews?DNA sequence variants in PPARGC1A, a gene encoding a coactivator of the ω-3 LCPUFA sensing PPAR-RXR transcription complex, are associated with NV AMD and AMD-associated loci in genes of complement and VEGF signaling pathways.Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability.Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration.Angiogenesis inhibitors and the need for anti-angiogenic therapeutics.The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice.Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery.A Role for PPARbeta/delta in Ocular AngiogenesisThe cost-effectiveness of Welcome to Medicare visual acuity screening and a possible alternative welcome to medicare eye evaluation among persons without diagnosed diabetes mellitusRecent progress in macular function self-assessment.Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response.Treatment of age-related macular degeneration: focus on ranibizumabAntibody-based immunosuppressive agents for corneal transplantation.A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal Pigment Epithelium as a Novel Target for Reducing Choroidal Neovascularization in Age-Related Macular Degeneration.The national and subnational prevalence and burden of age–related macular degeneration in China.Interventions for neovascular age‐related macular degeneration.
P2860
Q26825644-727BA57E-71FE-4435-A2F5-4D58D19C8400Q28388335-74193FBC-0814-44E0-889D-FA8796158B55Q33353392-8AA80A33-992B-4678-86D8-0EA0DDA8B2ABQ33443692-DA51E967-9ECC-4858-9159-5B6A5C576E7FQ33847455-75830604-EC90-42C5-A88D-D1FD7602971DQ34097675-8C8C89E5-857A-4C76-B48D-8C39A7DC6D63Q34510579-E3AB75C7-E239-45F5-BD27-4BF6DC377988Q34555655-853794C5-0D31-4A7F-AB6F-9DB4638F197DQ35696092-C27820C7-F460-4656-8E8C-95628FC75078Q36193438-1C6DEC21-0CF5-42C4-8B5A-D6CF00B644CCQ36949560-A9E1D61A-796B-4ADC-A316-C0505FE73EEFQ36977441-D4B6DE4C-3391-40D2-A0D1-BE7E6FCE60D5Q37121790-DA301391-5231-4F14-9C0B-DA3916533F63Q37125975-644AA9B9-6F5F-4A8C-9143-882FD084F739Q37138072-AD23DE83-866F-40CE-A699-E1F324CD25A1Q37143541-86867B38-2E23-4AEF-8CAD-F1FC6E4C12ACQ37184559-6791110C-C9C7-4E28-9232-D9D126C636CAQ37233230-13471F7E-CCAF-40F8-B776-1D8F164C0809Q37366343-9B0424B8-13C5-4652-9F1B-9C00E1A90AC5Q38663964-3EAA4412-7F2B-4CE1-A293-49BCF1FDC50AQ47102759-28144348-1851-4A72-9128-DA3272A78483Q59305357-9C2ECB83-181B-4928-B4FE-CB12519861BC
P2860
Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Pegaptanib and ranibizumab for ...... eneration: a systematic review
@ast
Pegaptanib and ranibizumab for ...... eneration: a systematic review
@en
Pegaptanib and ranibizumab for ...... eneration: a systematic review
@nl
type
label
Pegaptanib and ranibizumab for ...... eneration: a systematic review
@ast
Pegaptanib and ranibizumab for ...... eneration: a systematic review
@en
Pegaptanib and ranibizumab for ...... eneration: a systematic review
@nl
prefLabel
Pegaptanib and ranibizumab for ...... eneration: a systematic review
@ast
Pegaptanib and ranibizumab for ...... eneration: a systematic review
@en
Pegaptanib and ranibizumab for ...... eneration: a systematic review
@nl
P2093
P2860
P356
P1476
Pegaptanib and ranibizumab for ...... eneration: a systematic review
@en
P2093
P2860
P304
P356
10.1136/BJO.2007.118562
P407
P577
2007-09-01T00:00:00Z